Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04990609 · ClinicalTrials.gov registry record · Phase 2

EUS-RFA PANCARDINAL-1 Trial

A Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by The University of Texas Health Science Center, Houston.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT04990609: Recruiting Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by The University of Texas Health Science Center, Houston.

NCT04990609 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC) that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 60 participants, below the 293-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04990609, a Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC), is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective.

Interventions

  • DRUG Neoadjuvant Chemotherapy (NAC)
  • DEVICE Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)

Study Locations (1)

Texas

  • Memorial Hermann Hospital - Houston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2021-08-13
Est. Completion 2028-05-30
Phase Phase 2

What NCT04990609 shows while recruiting

NCT04990609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 293-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma (PDAC) appearing as the primary indexed condition, and to 2 interventions - of which Neoadjuvant Chemotherapy (NAC) is the first listed.

NCT04990609 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04990609 about?

NCT04990609 is a clinical study titled "EUS-RFA PANCARDINAL-1 Trial". The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS)...

What is the current status of trial NCT04990609?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2021-08-13. Estimated completion is 2028-05-30.

What conditions does trial NCT04990609 study?

This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma (PDAC).

What interventions are being tested in trial NCT04990609?

The interventions under investigation include: Neoadjuvant Chemotherapy (NAC) (DRUG), Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) (DEVICE).

Who is sponsoring clinical trial NCT04990609?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04990609 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Ductal Adenocarcinoma (PDAC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04990609's enrollment target sits among peer trials

60 11th of 16 higher than 6 of 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Ductal Adenocarcinoma (PDAC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04990609, the US trial registry maintained by the National Library of Medicine. NCT04990609 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.